XFLH Capital Corporation announced on September 18, 2026, that it has entered into a non-binding letter of intent (LOI) with Renogen Biolab Inc. for a proposed business combination. Renogen Biolab is a Canadian health service provider specializing in molecular capabilities, including DNA services, vector engineering, and protein expression.
Under the terms of the LOI, the parties have agreed to use their reasonable best efforts to negotiate definitive agreements as soon as possible. Both entities will also provide reasonable access to information for the purpose of conducting due diligence inquiries.
XFLH Capital Corporation is a publicly traded special purpose acquisition company (SPAC) incorporated under the laws of the Cayman Islands. The company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
